Does thrombin play a role in the pathogenesis of brain damage after periventricular hemorrhage?
Neonatal periventricular hemorrhage (PVH) is a devastating complication of prematurity in the human infant. Based upon observations made primarily in adult rodents and the fact that the immature brain uses proteolytic systems for cell migration and growth, we hypothesized that thrombin and plasmin enzyme activities contribute to the brain damage after PVH. The viability of mixed brain cells derived from newborn rat periventricular region was suppressed by whole blood and thrombin, but not plasmin. Following injection of autologous blood into the periventricular region of newborn rat brain, proteolytic activity was detected in a halo around the hematoma using membrane overlays impregnated with thrombin and plasmin fluorogenic substrates. Two-day old rats received periventricular injection of blood, thrombin, and plasminogen. After 2 days, thrombin and blood were associated with significantly greater damage than saline or plasminogen. Two-day old mice received intracerebral injections of blood in combination with saline or the proteolytic inhibitors hirudin, alpha2macroglobulin, or plasminogen activator inhibitor-1. After 2 days, hirudin significantly reduced brain cell death and inflammation. Two-day-old mice then received low and high doses of hirudin mixed with blood after which behavioral testing was conducted repeatedly. At 10 weeks there was no statistically significant evidence for behavioral or structural brain protection. These results indicate that thrombin likely plays a role in neonatal periventricular brain damage following PVH. However, additional factors are likely important in the recovery from this result.
Xue
Mengzhou
M
Department of Pathology, University of Manitoba, Winnipeg, Canada.
Balasubramaniam
Janani
J
Parsons
Kari A L
KA
McIntyre
Ian W
IW
Peeling
James
J
Del Bigio
Marc R
MR
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D002478:Cells, Cultured; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006629:Hirudins / Q000494:pharmacology*; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D051381:Rats; D017207:Rats, Sprague-Dawley; D012697:Serine Endopeptidases / Q000378:metabolism; D013917:Thrombin / Q000378:metabolism*
D005343:Fibrinolytic Agents; D006629:Hirudins; D012697:Serine Endopeptidases; D013917:Thrombin